recipient was treated with STI571, and a complete cytogenetic and molecular remission was achieved three and six months later, respectively. Now, more than one year after the transplantation, the patient is well, without any sign of chronic graft-versus-host disease, and is heterozygous for sickle cell disease (the status of the donor). The donor initially received interferon alfa but did not tolerate it and then received STI571; a complete cytogenetic response was achieved, but a complete molecular response has not yet occurred.
Transmission of acute myeloid leukemia as well as T-cell lymphoma through bone marrow transplantation has been reported previously. 2, 5 However, this case shows that chronic myeloid leukemia can also be transmitted through transplantation of peripheral-blood stem cells from a donor with no sign of chronic myeloid leukemia in the peripheral blood. This raises the issue of routine bone marrow and karyotype examination in donors of peripheral-blood stem cells. 4 However dramatic such cases are, it would be costly and ineffective, as well * ND denotes not done. † The normal range is 200 to 440 U per liter. 
